U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C36H47N5O4
Molecular Weight 613.7895
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of INDINAVIR ANHYDROUS

SMILES

CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H]4[C@H](O)CC5=CC=CC=C45

InChI

InChIKey=CBVCZFGXHXORBI-PXQQMZJSSA-N
InChI=1S/C36H47N5O4/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45)/t28-,29+,31+,32-,33+/m1/s1

HIDE SMILES / InChI

Molecular Formula C36H47N5O4
Molecular Weight 613.7895
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Indinavir is an antiretroviral drug for the treatment of HIV infection. Indinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Indinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
47.9 µM [Ki]
0.37 nM [Ki]
100.0 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CRIXIVAN®

Cmax

ValueDoseCo-administeredAnalytePopulation
12617 nM
800 mg 3 times / day steady-state, oral
INDINAVIR plasma
Homo sapiens
17181 nM
500 mg/m² 3 times / day multiple, oral
INDINAVIR plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
30691 nM × h
800 mg 3 times / day steady-state, oral
INDINAVIR plasma
Homo sapiens
38742 nM × h
500 mg/m² 3 times / day multiple, oral
INDINAVIR plasma
Homo sapiens
9231 nM × h
800 mg 3 times / day multiple, oral
INDINAVIR unknown
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
40%
800 mg 3 times / day steady-state, oral
INDINAVIR plasma
Homo sapiens

Doses

AEs

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​

Drug as victim

PubMed

Sample Use Guides

In Vivo Use Guide
Usual Adult Dose for HIV Infection 800 mg orally every 8 hours or indinavir 800 mg plus ritonavir 100 to 200 mg orally every 12 hours
Route of Administration: Oral
In Vitro Use Guide
Indinavir (10 nM) gave 14% inhibition of HIV replication alone and 81% in combination with P-gp/MRP inhibitors.
Substance Class Chemical
Record UNII
9MG78X43ZT
Record Status Validated (UNII)
Record Version